Sun Exposure
Strict sun avoidance and unchecked tanning are probably both wrong answers: sun avoiders appear to die earlier, mostly of heart disease, while people who burn die earlier of skin cancer — though the first half of that rests entirely on observational data. The optimum is short, frequent, sub-burning exposure to a lot of skin, with sunscreen reserved for longer outdoor stretches.
The traditional dermatological position has been "the safest sun is no sun," and it stands up well for one outcome: melanoma and non-melanoma skin cancer scale roughly with cumulative UV dose. But long-running European cohorts point to strict avoidance being itself a measurable risk factor for all-cause and cardiovascular mortality; for deaths from cancers other than skin cancer, the studies disagree. Read alongside the evidence on cumulative damage, the data are often summarised as J-shaped — low exposure bad, very high exposure bad, a non-burning middle best — but only the low end is consistent: the one large cohort that measured time outdoors found the fall in overall death levelling off at high exposure rather than reversing, and the rise in overall death at the top rests on one study that used visible skin damage as its marker. A newer UK Biobank analysis — still an unreviewed preprint — finds the protective half of that curve but not the harmful half. The caveat is that the mortality evidence is entirely observational, and the most rigorous recent synthesis judged it mixed and insufficient to justify changing sun-protection guidance — so the framing below is a defensible reading of confounded data, not a settled fact.
What the evidence actually supports
Strong:
- Strict sun avoidance is associated with higher all-cause mortality in observational cohorts. The Melanoma in Southern Sweden (MISS) cohort followed 29,518 Swedish women for about 20 years; avoiders of sun exposure had roughly double the mortality of the highest-exposure group (HR 2.0, 95% CI 1.6–2.5), and those with moderate exposure a 40% higher rate (HR 1.4, 95% CI 1.1–1.7)[1]. The range printed after each ratio is its 95% confidence interval — the span in which the true effect most plausibly sits; when that span crosses 1.0, the result is compatible with no effect at all. A follow-up analysis found the survival gap sat almost entirely in cardiovascular and other non-cancer deaths, and put the life-expectancy cost of avoidance at 0.6–2.1 years[2]. The signal is biologically plausible but "avoidance" was self-reported and correlates with indoor lifestyle, lower activity, and comorbidity, so reverse causation and confounding are live concerns. A 2025 study pairing US survey data with a genetic (Mendelian randomisation) analysis found that people who sought shade less often reported less cardiovascular disease, but the genetic analysis found no evidence that sun exposure itself caused the difference [3]. A 2026 review of 28 studies found mostly protective associations but cautioned that the healthy-user effect and socioeconomic differences could explain part of them [4].
- Cumulative UV is the dominant driver of visible skin aging. UV ages skin by switching on collagen-degrading enzymes (matrix metalloproteinases) in the dermis [5]. One study of 298 white women aged 30–78, run by cosmetics-company researchers, put UV's share of visible facial aging signs at about 80%: sun spots and uneven pigmentation tracked sun exposure, wrinkles and texture reflected both sun and age, and sagging tracked age rather than sun [6]. Sun-damaged skin looks different from naturally aged skin (leathery rather than thin), but both show the same kind of cumulative collagen damage [7].
- Without sun or supplements, low vitamin D is common at temperate latitudes. Low vitamin D is common where winter sun is weak: in standardised blood data pooled from 18 European population studies (55,844 people), about 13% were below 30 nmol/L across the year (18% of those sampled October-March) and 40% were below 50 nmol/L [8].
Moderate:
- Strict avoidance tracks with higher death rates; whether risk rises again at high exposure is uncertain. At the high end, the evidence is one proxy study. Markers of cumulative excess UV track with mortality: in the first National Health and Nutrition Examination Survey (NHANES I) follow-up of 8,472 white participants (1971–1992), severe sun damage visible on examination — sun spots, thread veins, coarsened texture — carried about 45% higher all-cause mortality (HR 1.45, 95% CI 1.22–1.72) and moderate damage 20% higher (HR 1.20, 95% CI 1.08–1.32)[9]. Smoking was adjusted for and does not appear to drive that association, but visible damage remains a crude proxy for a lifetime UV dose nobody measured. The caveat that downgrades this from Strong: the leading 2025 systematic review — 55 studies, overwhelmingly ecological, not a single randomised trial among them — found the mortality evidence "too variable to provide a rationale for changes to sun protection guidance," with all included studies at some-to-very-high risk of bias[10].
- Low vitamin D is partly a marker of low UV exposure; extra vitamin D helps little once you are not deficient. Randomised and genetic evidence converge here: in the 25,871-participant VITAL trial, 2000 IU/day vitamin D3 left total invasive cancer essentially unchanged — a 4% difference well inside the range expected from chance (HR 0.96, 95% CI 0.88–1.06) — and did not reduce major cardiovascular events, leaving only a non-significant hint of fewer cancer deaths (about 17% fewer, HR 0.83, 95% CI 0.67–1.02)[11]. Non-linear Mendelian randomization in the UK Biobank (n=307,601) found an L-shaped relationship — genetically low 25-hydroxyvitamin D, the standard blood measure of vitamin D status, raised mortality only in the deficient range, with no benefit from raising already-adequate levels[12]. The big supplement trials mostly enrolled people who already had enough vitamin D. In D-Health, 21,315 Australians aged 60 to 84 took monthly vitamin D3 for about 5 years; the placebo group averaged 77 nmol/L, and deaths were not lower (HR 1.04, 95% CI 0.93–1.18) [13]. Heart attacks, strokes and artery-opening procedures were possibly about 9% lower, but the result could be chance (HR 0.91, 95% CI 0.81–1.01) [14]. Re-running these trials in UK Biobank data reproduced the null results only when the population was weighted to be similarly replete [15]. So the null trials fit two explanations, which may both be true: vitamin D may matter mainly when you are deficient, and sunlight may also work through other routes (nitric oxide, the body clock, immune effects) that a pill does not replace.
- For most melanomas, intermittent burning drives the risk more than steady exposure does, but steady exposure is not harmless. The foundational meta-analysis of 57 studies found intermittent sun exposure raised melanoma risk by about 60% (summary RR 1.61, 95% CI 1.31–1.99), while chronic outdoor and occupational exposure showed no association and if anything a slight protective tilt (RR 0.95, 95% CI 0.87–1.04). Sunburn history was a consistent risk factor throughout[16]. That neutral average hides opposite effects by melanoma type. A 2026 review found occupational sun exposure linked to about 45% higher melanoma risk in pooled studies that included lentigo maligna melanoma, the type that grows on chronically sun-damaged skin (RR 1.45, 95% CI 1.08–1.94), and to lower risk in studies that left it out (RR 0.69, 95% CI 0.55–0.86); its lead author has given expert testimony on the question [17]. Steady exposure also drives squamous-cell skin cancer: in a randomised trial, daily sunscreen led to about 40% fewer squamous-cell tumours [18].
- UVA light releases nitric oxide from the skin, but a lasting blood-pressure benefit is unproven. Skin holds abundant stores of nitrogen-oxide compounds that UVA releases as nitric oxide, which relaxes blood vessels. In 24 healthy volunteers, a single session of UVA (two "standard erythemal doses", a fixed laboratory measure of UV) lowered blood pressure for a short time, and high blood pressure is more common at high latitudes and in winter [19]. But in 13 people with mildly high blood pressure, 2 weeks of daily UVA did not change 24-hour blood pressure; clinic readings dipped only shortly after irradiation [20]. A 2026 review of 14 studies found that most reported a fall but results were inconsistent, and called for larger trials [21]. At population scale, an analysis of 342,457 dialysis patients across 2,178 US clinics found ambient UV linearly and inversely associated with pre-dialysis systolic blood pressure even after adjusting for temperature [22]. The mechanism is genuine, but the population-level association is modest — on the order of a single millimetre of mercury across a seasonal swing, not the double-digit drop the raw regression coefficients look like at first glance. There is no individual UV dosimetry, and several authors hold relevant commercial ties (AOBiome, Relaxsol, Fresenius), so residual confounding remains live.
- UV exposure activates a real skin-brain axis. On UV exposure, keratinocytes locally synthesise corticotropin-releasing hormone, proopiomelanocortin, β-endorphin, and serotonin, and UVB induces β-endorphin in human skin. The opioid-like analgesia, naloxone-precipitated withdrawal, and conditioned aversion that define "UV addiction," however, come from mice; human relevance is inferred rather than demonstrated, and the human-focused syntheses are reviews, not outcome trials[23][24].
- Bright morning sun anchors the circadian clock. Daylight intensity at the eyes, sensed by a dedicated class of light-detecting retinal cells, suppresses morning melatonin and sets the evening melatonin rise. This is the single highest-leverage cue for sleep timing — see Circadian rhythms.
Weak / preliminary:
- Non-classical UVB photoproducts (lumisterol, tachysterol) act through a different set of nuclear receptors from the classical vitamin D receptor — receptors that switch on antioxidant and anti-inflammatory gene programmes — and appear photoprotective in mechanistic and cell-culture work[25]. Whether this matters clinically, i.e. whether sun-derived and oral vitamin D differ in long-term outcomes, is unsettled.
- Oral systemic photoprotectants — Polypodium leucotomos extract (PLE), astaxanthin, oral nicotinamide — rest on small, short trials. In industry-funded trials of PLE and astaxanthin, the skin tolerated a somewhat larger UV dose before reddening: in 54 fair-skinned adults, the dose needed rose about 24% over 8 weeks on a combination of PLE, red-orange extract and vitamins (the abstract gives no direct comparison with placebo) [26], and it was higher than with placebo after 9 weeks of 4 mg/day astaxanthin in 23 Japanese adults [27]. A 2025 review of 47 human studies judged the evidence limited by small samples and short duration [28]. Nicotinamide modestly cut new skin cancers in people who had already had them, but not in organ-transplant recipients (see Practical guidance). None of these substitutes for sunscreen.
Caution:
- Tanning beds, solarium use, and any history of sunburn elevate melanoma risk and should be treated as straightforwardly harmful. Pooled across 27 studies, ever having used a sunbed raised melanoma risk by about 20%, and starting before age 35 by about 87%[29]. A larger 2021 pooled analysis of 36 melanoma studies found a similar link (about 27% higher risk). It also found about 58% higher risk of squamous-cell skin cancer, and the links were strongest for skin cancers diagnosed before age 50[30].
- Familial melanoma, a dense crop of irregular moles, very pale skin (types I–II on the Fitzpatrick skin-tone scale), or immunosuppression: there is no known "safe" intentional UV dose. Vitamin D status should be managed via oral supplementation, not sun[31].
Sun exposure and mortality
Evidence: Moderate that strict avoidance itself raises death rates (the association is consistent; causation is unproven); Weak for a rise at high exposure and for any specific dose.
The evidence base on sun and mortality has shifted because the methodology improved. Early cohorts approximated lifetime UV exposure with proxies like birth year — which conflates UV with everything else that changed across the 20th century (indoor work, diet, smoking, screening intensity). The MISS cohort improved on that with structured sun-habit interviews. UK Biobank's Sun-BEEM index is a four-item exposure score (time outdoors, residential ambient UV, solarium use, sun-protection use); in 419,007 White-European participants it found a monotonic inverse dose-response for all-cause mortality — roughly 11% lower at medium exposure and 16% lower at high exposure compared with low (HR 0.89 and 0.84) — rather than a J-curve, with no clear dose-response for skin-cancer mortality but rising keratinocyte (non-melanoma) skin cancers. This is a medRxiv preprint that has not been peer-reviewed, so treat it as preliminary and not on the same footing as the published cohorts above[32]. A peer-reviewed cohort that measured time outdoors points the same way on overall death. In 83,205 Seventh-day Adventists in the US and Canada, spending about 2 hours a day outdoors in summer rather than 30 minutes was linked with about 10% lower all-cause death (HR 0.90, 95% CI 0.86–0.93) and 11% lower cardiovascular death (HR 0.89, 95% CI 0.83–0.95), after accounting for physical activity. The benefit levelled off rather than reversing: 5 hours a day carried the same all-cause figure (HR 0.90, 95% CI 0.85–0.95). Cancer death was not lower at 2 hours (HR 1.02, 95% CI 0.93–1.13) and was about 15% higher at 5 hours (HR 1.15, 95% CI 1.02–1.29) [33].
The better cohorts point broadly the same way, though not on every row:
| Outcome | Moderate, non-burning UV | Sunburn / chronic excess | Strict avoidance |
|---|---|---|---|
| All-cause mortality | Lower | Higher in one US study that used visible skin damage as its marker; flat in a cohort that measured time outdoors | Higher |
| Cardiovascular mortality | Lower | Mixed | Higher |
| Deaths from cancers other than skin cancer | Unclear — studies disagree | Mixed | Not clearly higher |
| Cutaneous melanoma | Mixed: lower in some studies of steady exposure, higher once melanoma on chronically sun-damaged skin is counted | Sharply higher | Lower |
| Non-melanoma skin cancer | Higher with cumulative dose | Sharply higher | Lower |
Skin-cancer risk and mortality risk move in opposite directions, and for a population without high melanoma genetic risk the observational balance tilts toward moderate exposure being net-positive. That said, the most rigorous synthesis to date is more cautious: across 55 studies (overwhelmingly ecological, no RCTs) the 2025 NIHR systematic review found roughly as many analyses pointing to benefit as to harm, judged every included study at some-to-very-high risk of bias, and concluded the evidence is too variable to warrant changing sun-protection guidance[34]. The table reflects the direction of the better cohorts, not a settled consensus.
Why sun-derived vitamin D is not the same as a pill
Evidence: Strong for the kinetic difference; Weak for it mattering to any hard outcome.
Cutaneous vitamin D synthesis is a photochemical cascade: UVB (~290–315 nm) opens the B-ring of 7-dehydrocholesterol in epidermal keratinocyte and fibroblast membranes, generating previtamin D3, which rearranges itself over the following hours, driven by body heat alone, into cholecalciferol — vitamin D3 proper. The molecule is then released slowly to the bloodstream bound to vitamin-D-binding protein (DBP).
Three proposed differences from oral D3 (the third is untested):
- Sustained kinetics. The tracer study behind this claim irradiated seven volunteers and found that skin-made D3 travels in plasma almost entirely on DBP, giving slower delivery to the liver and a more sustained rise in circulating 25-hydroxyvitamin D; orally dosed vitamin D instead partitions into chylomicrons and lipoproteins and clears within roughly a day[35]. The direction is well established. The widely repeated "2–3× longer half-life" figure is not — no head-to-head study has measured it, and the oral comparator in that experiment was vitamin D2 rather than D3.
- No toxicity ceiling. Excess UVB photodegrades surplus previtamin D3 into lumisterol and tachysterol — sun cannot cause hypervitaminosis D [36]. Oral D3, by contrast, can.
- Local use in the skin. Skin cells do not just make vitamin D for the blood. Many of them also turn it into its active form on the spot, where it acts locally on a range of cell functions [37]. Whether vitamin D taken by mouth supports these local skin effects as well as sun-made vitamin D has not been tested.
Lumisterol and tachysterol, long dismissed as inert byproducts, are increasingly recognised as signalling molecules in their own right, binding a separate family of nuclear receptors that drive antioxidant and anti-inflammatory responses in skin[38]. Whether this translates to differences in clinical outcomes between sun-derived and supplemented vitamin D is not yet established.
Practical implication. Avoid running low on vitamin D in winter. Most people do not need routine blood tests for this: the Endocrine Society's 2024 guideline advises against routine vitamin D testing unless a doctor has a specific medical reason, because no target blood level has been shown to prevent disease, and it advises against doses above the standard daily recommendation for healthy adults under 75 [39]. Beyond roughly 40° of latitude, north or south, sunlight is too weak to maintain vitamin D status in at least some winter months for everyone regardless of skin type — and further poleward the dead zone widens to roughly October through March — so oral vitamin D3 across the winter is the standard fix; see Vitamin D. Do not try to "bank" D in summer by deliberate overexposure: the photodegradation fail-safe means extra burning yields extra skin damage, not extra D[40].
Cardiovascular and metabolic effects independent of vitamin D
Evidence: Moderate for the mechanism and for a small population-level association; Weak for a lasting blood-pressure effect from sun exposure.
UVA is the longer-wavelength, less DNA-damaging part of the spectrum, and it does something distinct: it photolyses cutaneous nitrogen-oxide stores into bioactive nitric oxide, which diffuses systemically and triggers arterial vasodilation. This is one proposed contributor to the latitude and seasonal blood-pressure gradients seen across many populations. Blood pressure runs higher in winter and lower in summer: across 47 studies of 856,539 people, clinic readings were about 5.6 mmHg systolic and 3.3 mmHg diastolic lower in summer (pooled from the 29 studies with clinic readings) [41]. That comparison does not separate sunlight from heat; the one analysis below that adjusts for temperature finds that heat explains more of the swing than UV does.
The effect is consistent enough to be visible in a 342,457-patient haemodialysis cohort with routine clinic blood-pressure recordings, where incident UV was inversely and linearly associated with pre-dialysis systolic pressure after adjustment for ambient temperature, age, sex, and body-mass index[42]. Worth keeping the scale honest, because the published coefficients are easy to misread: they are expressed per 100 W/m² of incident UVB, while actual UVB at these clinics averaged about 15 W/m² and swings by only a few W/m² between winter and summer. Translated back to that real-world range, and after removing the larger temperature contribution, the attributable movement is on the order of 1 mmHg. A genuine population-level signal, not a treatment.
A few small, short and mostly uncontrolled before-and-after studies hint at metabolic effects in people: LDL-cholesterol was lower after sun-exposure advice, and C-reactive protein and interleukin-6 (blood markers of inflammation) fell in psoriasis patients treated with narrowband UVB, though without control groups this may partly reflect the psoriasis itself improving [43]. In male mice on a high-fat diet, long-term UV curbed weight gain, glucose intolerance and insulin resistance, and many of these benefits were not reproduced by vitamin D supplements [44]. So low vitamin D in people with obesity or high blood pressure may partly mark too little UV rather than cause their metabolic disease — a hypothesis these studies raise but cannot settle.
Mood, sleep, and the skin-brain axis
Evidence: Strong for the local hormone cascade; Weak for UV-on-skin addiction and mood claims in humans; Moderate for bright light at the eyes in seasonal depression.
UV-exposed keratinocytes locally synthesise corticotropin-releasing hormone → proopiomelanocortin → β-endorphin and the two hormones that drive protective tanning; the skin runs its own miniature version of the brain's central stress axis. The β-endorphin reaches the systemic circulation and binds opioid receptors centrally — which is the proposed reason frequent sun exposure produces opioid-like analgesia and mood elevation, and why naloxone reliably triggers withdrawal in UV-habituated mice[45][46]. The withdrawal and reward findings are from mice; the human end of this is inference.
Human skin appears able to make serotonin from tryptophan. In 101 healthy men, the brain's serotonin turnover was lowest in winter and rose with hours of bright sunshine [47]. Light reaching the brain through the eyes is a plausible route; whether serotonin made in the skin adds to winter low mood is an unproven idea resting on preliminary data [48]. The tested benefit comes from bright light at the eyes, not UV on the skin. In 16 randomised trials (559 patients) of bright light therapy for depression with a seasonal pattern (formerly called seasonal affective disorder), a response was about 40% more likely than with placebo (RR 1.42), though the trials were at moderate-to-high risk of bias [49]. Added to usual treatment for non-seasonal depression, it raised remission from 23.5% to 40.7% (11 trials, 858 patients) [50]; see Circadian rhythms.
For sleep specifically: bright morning sunlight at the eyes is the strongest single time cue the body clock has. A dedicated nerve pathway carries the signal from the retina to the clock nucleus in the hypothalamus, which then sets the evening melatonin rise that allows sleep onset 14–16 hours later. The dose that matters is daytime brightness (10,000+ lux outdoors vs. 100–500 lux indoors), not UV per se — see Circadian rhythms.
What UV actually does to skin
Evidence: Strong — the mechanisms here are settled cell and molecular biology (the circadian-repair point is mouse-only).
The visible signs of "old skin" — coarse wrinkling, leathery texture, sun spots, and the fine broken surface veins called telangiectasias — are mostly photoaging; sagging, by contrast, tracks age more than sun. Compare sun-protected skin (e.g., the underside of an upper arm) with sun-exposed skin (the back of the same hand) in any 70-year-old: the difference is the cumulative UV history.
Mechanism. UV photons drive an immediate burst of reactive oxygen species in the epidermis and upper dermis. Those free radicals switch on a stress-signalling cascade that ends at two transcription factors — the master switches that decide which genes a cell transcribes. Their combined output is to:
- Massively upregulate MMP-1, the collagenase that makes the first cut in intact fibrillar collagen — the dermis's main load-bearing protein.
- Upregulate MMP-3 (stromelysin-1) — breaks down proteoglycans and fibronectin, and activates other latent MMPs.
- Upregulate MMP-9 (gelatinase B) — finishes off the fragmented collagen pieces.
- Down-regulate fibroblast procollagen synthesis at the same time, producing a structural deficit[51].
UV also covalently modifies the collagen that survives, permanently oxidising specific amino-acid sites along the fibre in a way that disrupts how fibroblasts grip and contract the matrix[52]. The matrix doesn't just thin; it stops working.
UVA penetrates deeply into the dermis and is the dominant driver of these changes. UVB penetrates less but causes most of the direct DNA damage — welding adjacent bases together into lesions the cell must cut out and rebuild — and is the dominant driver of skin cancer.
UV is also immunosuppressive. UVB-induced DNA damage triggers systemic, antigen-specific T-cell-mediated immunosuppression. The clinical signature is stark: solid-organ transplant recipients, who are pharmacologically immunosuppressed, develop cutaneous squamous-cell carcinoma at more than 65 times the background rate, with a smaller but real excess of basal-cell carcinoma[53] — direct evidence that immune surveillance normally restrains UV-driven skin cancer. This is a distinct hazard from photoaging and from the direct mutagenesis above, and it is part of why a healthy immune system tolerates incidental sun that an immunosuppressed one cannot.
Repair may run on a clock. In mice, the system that repairs UV damage to DNA rises and falls over the day, and mice irradiated at 4 AM, when their repair was low, got about five times as many skin cancers as mice irradiated at 4 PM [54]. Mice are active at night, and the mouse pattern may not simply flip for people [55]. Small human studies disagree on whether morning or evening UV causes more redness [56] [57], so timing UV exposure around a repair rhythm is not yet a practical lever.
Skin type changes everything
Evidence: Strong — skin pigmentation is the single largest modifier of every trade-off on this page.
The Fitzpatrick scale tracks the eumelanin / pheomelanin balance. Lighter skin (Types I–III) is heavier in pheomelanin, which is a pro-oxidant under UV and amplifies free-radical damage. Darker skin (Types IV–VI) is heavier in eumelanin, a broad-spectrum filter and antioxidant.
Two practical numbers:
- Innate sun protection factor (SPF). Type I/II skin has an intrinsic SPF of about 3.3. Type V/VI skin has roughly 13.4. Eumelanin functions as built-in sunscreen[58].
- Vitamin D synthesis time. Deeply pigmented skin needs several times the UVB exposure of pale skin to make the same amount of vitamin D. The best modelling estimates put the penalty at roughly three- to fivefold: the exposure-time model scales type V by about 2.5× and type VI by about 4×, and its worked equatorial example runs from about 3 minutes at noon for the palest skin to about 15 minutes for the darkest. Blanket sun-avoidance guidelines apply that penalty without compensating with stronger oral repletion advice — which is part of why severe vitamin D deficiency is endemic in dark-skinned populations at temperate latitudes[59].
The 2024 revised Australian position statement formalises this with three risk groups[60]:
- Very high skin-cancer risk — Fitzpatrick I/II, immunosuppression, melanoma history, a dense crop of atypical moles. Year-round photoprotection; manage vitamin D with supplements.
- High vitamin-D-deficiency risk, low skin-cancer risk — Fitzpatrick V/VI. Routine daily sunscreen during ordinary outdoor activity is discouraged; deliberate brief unprotected exposure to maintain vitamin D status is appropriate.
- Intermediate — most of the population. Sub-erythemal exposure — short of the dose that reddens the skin — during incidental outdoor activity for systemic benefit; sunscreen for longer outdoor stretches and high UV index.
Practical guidance
Evidence: Moderate — the direction is well supported; the specific minute counts are modelled population averages, not measured doses.
Aim for micro-doses, not "tans"
Skin production of vitamin D levels off within a single exposure: under prolonged simulated sunlight, previtamin D3 plateaus at about 10–15% of its skin precursor (7-dehydrocholesterol), and the excess is converted into other compounds [61]. Staying out longer does not keep raising vitamin D, but it does keep raising skin-cancer risk, while exposing more skin generally makes more vitamin D — so a few minutes of sun on a larger area of skin is the efficient pattern, not long sessions [62].
Once the UV index is 3 or higher, most people keep adequate vitamin D with just a few minutes outdoors on most days [63]. The best modelling, for lighter skin (types I–IV) with about a third of the skin uncovered (shorts and T-shirt) at noon under clear sky, gives these daily times [64]:
| Situation | Approximate daily exposure for vitamin D |
|---|---|
| UV index below 2 | Almost no vitamin D is made |
| Summer at mid-latitudes (UV index 3+) | About 4–6 min (about 3 min near the equator) |
| Spring and autumn around 50° latitude | About 8–15 min |
| Winter above about 40° latitude | Not enough UVB in at least some months; rely on oral vitamin D |
| Darker skin | About 2.5× longer for type V, about 4× for type VI |
| Cloud | Up to about 60% longer at high latitudes |
These are population approximations from exposure modelling, not titratable prescriptions: real dose varies widely with how much skin is uncovered, age (the 7-dehydrocholesterol supply in skin declines over the years), and skin type, and the modellers' own conclusion is that precise self-titration is impractical. Spread exposure across the week; do not "stack" it. Time between sessions is what lets DNA repair clear UV-induced lesions before they accumulate.
Protect when exposure exceeds the synthesis dose
Once you're past the brief window that buys vitamin D — long beach days, alpine hiking, sustained outdoor work — the calculation flips and the goal is photoprotection.
- Broad-spectrum sunscreen (UVA + UVB). This is the one sun habit tested in a long-term randomised trial. In the Nambour trial of 1,621 Queensland adults, daily SPF 15+ sunscreen on the head, neck, arms and hands for 4.5 years led to about 40% fewer squamous-cell skin cancer tumours, with no effect on basal-cell carcinoma [65]. Ten years on, the daily group had about half as many melanomas (11 vs 22; HR 0.50, borderline significance) [66]. In participants under 55, skin aging was about 24% less [67]. All of this comes from one trial with small numbers of cancers. SPF 30–50 is sufficient for most skin types; SPF 50+ for Fitzpatrick I/II or with melanoma history. Older randomised trials of daily sunscreen at around SPF 16 found no effect on vitamin D [68], a 2025 pooled analysis of mixed study types points to a small drop [69], and the 2025 Sun-D randomised trial — the first to test high-SPF product — found that daily SPF 50+ use modestly lowered 25-hydroxyvitamin D — about 5 nmol/L lower than the control group over a year — and left more people below the deficiency threshold (45.7% vs 36.9%), so regular high-SPF users may need supplementation[70].
- Hat, long sleeves, UV-blocking sunglasses. A cheap way to cut UV to the skin and eyes; see Eye health below for what sun does to the eyes.
- Avoid sunburn. This is the single most useful bright line. Burning is the clearest warning sign for melanoma, but UV damage adds up even without reddening: squamous-cell skin cancer tracks cumulative dose, which is why daily sunscreen cut it in the Nambour trial above. Brief exposure is fine; long hours outdoors call for cover.
- No tanning beds, ever. Ever using one raises skin-cancer risk (see Caution above), and the risk-benefit balance is clearly negative.
Oral photoprotection — modest, and for specific groups
A small literature of short trials tests oral Polypodium leucotomos extract (PLE), astaxanthin, and oral nicotinamide as adjunct photoprotectants. Nicotinamide supports the energy-intensive DNA-repair machinery, and PLE — tested in skin cells and donated tissue, in combination with rooibos extract and by authors including one from the company that markets it — preserves vitamin D receptor levels in skin under oxidative stress[71]. The strongest datapoint by some distance is the ONTRAC trial in 386 patients with prior non-melanoma skin cancers, where 500 mg nicotinamide twice daily cut new non-melanoma skin cancers by 23% over a year (95% CI 4–38)[72]. That is a modest effect, and only in people who have already had skin cancer; it should not be generalised to healthy adults. In organ-transplant recipients, a small placebo-controlled trial (stopped early for poor recruitment) found no benefit: 207 vs 210 new cancers [73]. A large retrospective study of mostly older, male US veterans found about 14% fewer new skin cancers overall, and about 54% fewer when people started after their first skin cancer [74]. Nicotinamide is a daily preventive for people with past skin cancer, not a high-exposure-day add-on, and none of these supplements substitutes for sunscreen or for not burning.
Cautions and contraindications
- Personal or strong family history of melanoma, a dense crop of atypical moles, prior skin cancer, immunosuppression, photosensitising medications (some antibiotics, retinoids, the antiarrhythmic amiodarone, some anti-inflammatory painkillers, and the blood-pressure pill hydrochlorothiazide): treat sun primarily as a hazard. Get a yearly dermatology check; manage vitamin D with supplements. Long-term, high-dose hydrochlorothiazide is also linked to modestly more non-melanoma skin cancer, mainly squamous-cell, in studies from non-Asian countries — about 1.5 times the risk at the highest cumulative doses in a large Canadian cohort [75] [76]; a 2026 cohort saw the excess only in White patients [77]. Don't stop it on your own, but ask whether a different blood-pressure drug suits you if you burn easily.
- Pregnancy: moderate, non-burning sun is fine and relevant for vitamin D status. Watch for melasma, the blotchy facial pigmentation that sun and pregnancy hormones together provoke, especially in mid-tone to deep skin.
- Eye health: the front of the eye takes most of the UV, so that is where the damage shows: long-term sun exposure is firmly linked to cortical cataract (clouding at the edge of the lens) and pterygium (a growth over the white of the eye) [78], and outdoor work is a clear cataract risk factor [79]. The link to macular degeneration is uncertain: pooling 14 studies of 43,934 people found no clear rise in risk with more sunlight (odds ratio 1.10, 95% CI 0.98–1.23) [80]. Real UV-blocking sunglasses and a brimmed hat are cheap and worth wearing on bright days.
- Children: their thinner outer skin layer and longer lifetime ahead make avoiding sunburn the top priority; playing in the sun short of any reddening is fine and useful for vitamin D. Time outdoors also protects eyesight: adding 40 minutes of outdoor activity to the school day cut new short-sightedness over 3 years from 39.5% to 30.4% in 6-year-olds [81] (more in Vision).
What's overrated
- "Sunscreen causes vitamin D deficiency." Overstated, but no longer dismissible: daily SPF 50+ use does modestly lower 25-hydroxyvitamin D — roughly 5 nmol/L in the Sun-D trial — so it is a small real effect rather than a wholesale cause. Most population deficiency is still from indoor lifestyles and high latitude, not from sunscreen; regular high-SPF users simply have one more reason to keep oral D3 topped up.
- Tanning as a longevity strategy. Tans are visible UV damage; they are not the source of the possible cardiovascular and mood benefits of sun, which appear well short of the dose that reddens skin, long before tanning.
- "You can store vitamin D in summer for winter." Blood vitamin D (25-hydroxyvitamin D) has a half-life of only about 2 weeks, and the vitamin D held in body fat about 2 months, so a high-latitude summer cannot cover a high-latitude winter [82]. Use oral D3 across the dark months — see Vitamin D.
- Oral D as a full substitute for sun. It restores systemic 25-hydroxyvitamin D but doesn't reproduce UVA-driven nitric oxide, the skin-brain axis, daytime circadian entrainment, or, possibly, local vitamin D activity in the skin. Useful, necessary at temperate latitudes — but not a complete replacement. No trial has yet pitted sun against equivalent oral D3 on a hard endpoint. The Australian SEDS study was designed to do exactly that, randomising sun-exposure advice against vitamin D supplementation with immune and cardiometabolic outcomes, but it has published a protocol and no results in the decade since[83]. The question remains genuinely open, and nothing currently running looks likely to close it.
Further reading
- Hoel D, Berwick M, de Gruijl FR, Holick MF. The risks and benefits of sun exposure 2016. Dermato-Endocrinology 2016.[84]
- Lindqvist PG et al. Avoidance of sun exposure is a risk factor for all-cause mortality: results from the Melanoma in Southern Sweden cohort. J Intern Med 2014;276:77–86.[85]
- Lindqvist PG et al. Avoidance of sun exposure as a risk factor for major causes of death: a competing risk analysis of the MISS cohort. J Intern Med 2016;280:375–87.[86]
- He W et al. Actinic skin damage and mortality — the First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. PLoS One 2011;6:e19907.[87]
- Gandini S et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005.[88]
- Manson JE et al. Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL). NEJM 2019.[89]
- Sutherland JP, Zhou A, Hyppönen E. Vitamin D deficiency increases mortality risk in the UK Biobank: a nonlinear Mendelian randomization study. Ann Intern Med 2022.[90]
- Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest 1993;91:2552–5.[91]
- Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012;345:e4757.[92]
- Chen AC et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention (ONTRAC). NEJM 2015.[93]
- Green AC et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011.[94]
- Tran V et al. Effect of daily sunscreen application on vitamin D: findings from the open-label randomized controlled Sun-D Trial. Br J Dermatol 2025.[95]
- Weller RB et al. Does incident solar ultraviolet radiation lower blood pressure? J Am Heart Assoc 2020.[96]
- Slominski RM, Chen JY, Raman C, Slominski AT. Photo-neuro-immuno-endocrinology: how ultraviolet radiation regulates the body, brain, and immune system. PNAS 2024.[97]
- Fell GL, Robinson KC, Mao J, Woolf CJ, Fisher DE. Skin β-endorphin mediates addiction to UV light. Cell 2014;157:1527–34.[98]
- Reichrath J, Nürnberg B. Cutaneous vitamin D synthesis versus skin cancer development: the Janus faces of solar UV radiation. Dermato-Endocrinology 2009.[99]
- Kift RC, Webb AR. Globally estimated UVB exposure times required to maintain sufficiency in vitamin D levels. Nutrients 2024.[100]
- Neale RE et al. Balancing the risks and benefits of sun exposure: a revised position statement for Australian adults. Aust N Z J Public Health 2024.[101]
- Gu J et al. Risk–benefit balance of habitual ultraviolet exposure for cardiovascular, cancer, and skin cancer mortality: UK Biobank cohort study. medRxiv 2026 — preprint, not peer-reviewed.[102]
- Parkhouse T et al. The effects of sunlight exposure on mortality: a systematic review of epidemiological studies. NIHR Open Res 2025.[103]